Secukinumab showed superiority over Enbrel®
Novartis announced results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior ...
Novartis announced results from the head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior ...
Novartis and Malaria No More announced today the debut of the Power of One campaign, encouraging people around the world ...
GlaxoSmithKline (GSK) plc has announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA), part ...
Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the ...
The European Medicines Agency (EMA) and the United States Food and Drug Administration (US FDA) have published a joint question-and-answer ...
Novartis is the first company to earn global CEO Cancer Gold Standard accreditation by the non-profit organization CEO Roundtable on ...
Novartis has announced that results of a global Phase III study showed that Afinitor® (everolimus) did not extend overall survival ...
GlaxoSmithKline (GSK) has increased its commitment to the GAVI Alliance to provide vaccines to developing countries, helping to protect millions ...
Published in the European Journal of Heart Failure1, results from a new sub-analysis of the RE-LY®* trial demonstrate important benefits ...
New data on an emerging treatment that aims to fight colorectal cancer by stimulating the immune system have been presented ...
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.